Allegra receives orders for more than 100,000 face shields

|

Published 16-APR-2020 10:00 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

As a result of the severe and mounting disruption to the supply of personal protective equipment (PPE) due to COVID-19 challenges, Allegra Orthopaedics Limited (ASX:AMT) has commenced distribution of high-quality face shields which are Australian designed and manufactured.

Following an announcement by Allegra on Wednesday that it had received significant orders, currently standing at 105,000 face shields the company’s shares surged approximately 30% to close at 19.5 cents.

Providing further interest for investors were management’s comments that the company is in ongoing discussions with other major hospital groups who have also expressed great interest in the shields.

Healthcare workers rely heavily on PPE to protect themselves and patients from contracting and also transferring COVID-19.

These face shields that have been approved by the Therapeutic Goods Administration (TGA) have enabled Allegra to diversify its product range and provide Australian-made protective equipment to meet hospital needs now and into the future.

Allegra demonstrates its ability to adapt to market needs

Allegra’s principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line.

The company is also the exclusive distributors of Waldemar Link GmbH & Co. KG products in Australia.

Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions.

The Link products add to Allegra’s well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb.

The addition of face shields to Allegra’s product range is expected to partly offset the negative financial impact incurred by Allegra as a result of the Federal Government’s action to suspend all elective surgeries in both public and private hospitals.

Allegra chief executive Jenny Swain highlighted the company’s ability to diversify across different fields in saying, “We feel very proud to be able to supply Australian designed and manufactured face shields for our front line carers.

"The current demand for PPE illustrates the need for companies to be ready to diversify during this global uncertainty surrounding COVID-19.

"I am pleased to say that Allegra has been proactive in making this happen and more importantly, we are supporting Australian manufacturing.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X